Takeda Pharmaceutical (DB:TKDA) - Stock Price, News & Analysis

TKDA Stock Overview

Takeda Pharmaceutical Company Limited se dedica a la investigación, desarrollo, fabricación, comercialización y concesión de licencias externas de productos farmacéuticos en Japón y a escala internacional.

About the company

TKDA fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	1/6
Financial Health	3/6
Dividends	3/6

Rewards

Cotiza un 63% por debajo de nuestra estimación de su valor razonable

Se prevé un crecimiento anual de los beneficios de 22.03%

Risk Analysis

La deuda no está bien cubierta por el flujo de caja operativo

El dividendo de 4.24% no está bien cubierto por los beneficios o los flujos de caja

Grandes partidas extraordinarias que afectan a los resultados financieros

Los márgenes de beneficio (4.3%) son inferiores a los del año pasado (7%)

Takeda Pharmaceutical Company Limited Competitors

Merck KGaA

XTRA:MRK

€66.3b

Dermapharm Holding

XTRA:DMP

€1.8b

Sartorius

XTRA:SRT3

€21.2b

PharmaSGP Holding

XTRA:PSG

€273.6m

Price History & Performance

Summary of all time highs, changes and price drops for Takeda Pharmaceutical
Historical stock prices
Current Share Price	JP¥12.60
52 Week High	JP¥15.60
52 Week Low	JP¥12.30
Beta	0.54
1 Month Change	-5.97%
3 Month Change	-5.26%
1 Year Change	-15.44%
3 Year Change	-12.50%
5 Year Change	-24.10%
Change since IPO	-26.96%

Recent updates

Shareholder Returns

	TKDA	DE Pharmaceuticals	DE Market
7D	-2.3%	-5.8%	-0.6%
1Y	-15.4%	-31.3%	4.9%

Rentabilidad frente al sector: TKDA superó al sector German Pharmaceuticals , que obtuvo un rendimiento del -30.7% el año pasado.

Rentabilidad vs. Mercado: TKDA obtuvo unos resultados inferiores a los del mercado German, que fue del -1.4% el año pasado.

Price Volatility

Is TKDA's price volatile compared to industry and market?
TKDA volatility
TKDA Average Weekly Movement	3.8%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.7%
10% most volatile stocks in DE Market	9.6%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: TKDA no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de TKDA (4%) se ha mantenido estable durante el año pasado.

About the Company

Founded	Employees	CEO	Website
1781	49,095	Christophe Weber	https://www.takeda.com

Takeda Pharmaceutical Company Limited se dedica a la investigación, el desarrollo, la fabricación, la comercialización y la concesión de licencias externas de productos farmacéuticos en Japón y a escala internacional. Ofrece productos farmacéuticos en las áreas de gastroenterología, enfermedades raras, terapias derivadas del plasma, inmunología, oncología y neurociencia. La empresa suministra sus productos bajo las marcas Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix y Alunbrig.

Takeda Pharmaceutical Company Limited Fundamentals Summary

How do Takeda Pharmaceutical's earnings and revenue compare to its market cap?
TKDA fundamental statistics
Market cap	€39.54b
Earnings (TTM)	€1.08b
Revenue (TTM)	€25.29b

36.6x

P/E Ratio

1.6x

P/S Ratio

Is TKDA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TKDA income statement (TTM)
Revenue	JP¥4.17t
Cost of Revenue	JP¥1.34t
Gross Profit	JP¥2.82t
Other Expenses	JP¥2.65t
Earnings	JP¥178.22b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 09, 2024

Earnings per share (EPS)	113.59
Gross Margin	67.76%
Net Profit Margin	4.27%
Debt/Equity Ratio	69.2%

How did TKDA perform over the long term?

See historical performance and comparison

Dividends

4.5%

Current Dividend Yield

161%

Payout Ratio

TKDA Stock Overview

Rewards

Risk Analysis

Takeda Pharmaceutical Company Limited Competitors

XTRA:MRK

€66.3b

XTRA:DMP

€1.8b

XTRA:SRT3

€21.2b

XTRA:PSG

€273.6m

Price History & Performance

Recent News & Updates

Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (Tak-079), A Potential Best-In-Class Anti-Cd38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

FDA Approves Takeda's EOHILIA (budesonide Oral Suspension)

Recent updates

Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (Tak-079), A Potential Best-In-Class Anti-Cd38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

FDA Approves Takeda's EOHILIA (budesonide Oral Suspension)

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024

Takeda Pharmaceutical Company Limited Announces Chief Financial Officer Succession, Effective April 1, 2024

Takeda's Gammard Liquidid®? Approves by U.S. Fda for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

Takeda Announces U.S. Food and Drug Administration Approves Hyqvia® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]

Takeda Pharmaceutical Company Limited to Report Q2, 2025 Results on Oct 31, 2024

Takeda Receives Positive Chmp Opinion for Hyqvia as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

The European Commission Approves Label Update for Takhzyro®? (Lanadelumab), Expanding Its Use to A Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (Hae)

U.S. Fda Approves Takeda's Adzynma (Adamts13, Recombinant-Krhn) as the First and Only Recombinant Adamts13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombotic Thrombocytopenic Purpura

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Takeda Pharmaceutical Company Limited Announces Late-Breaking Data from Phase 2B Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis At American College of Rheumatology Convergence Annual Meeting

Takeda Pharmaceutical Company Limited Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on December 1, 2023 and Provides Year-End Dividend Guidance for the Year Ending March 31, 2024

Takeda Pharmaceutical Company Limited Announces European Commission Approves ADCETRIS (Brentuximab Vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

Takeda Pharmaceutical Company Limited Announces Phase 3 ADMIRE-CD II Study

Takeda Pharmaceutical Company Limited to Report Q3, 2024 Results on Feb 01, 2024

Takeda Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

Takeda Pharmaceutical Company Limited Announces U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

Takeda Announces Approval of CUVITRU Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema in Patients Aged 2 Years and Older

Takeda Announces FDA Acceptance of NDA Resubmission of Tak-721 (Budesonide Oral Suspension) for the Short-Term Treatment of Eosinophilic Esophagitis

Takeda Pharmaceutical Company Limited Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a highly selective oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Takeda Pharmaceutical Company Limited Announces Board Changes

Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

Takeda Pharmaceutical Company and Eli Lilly and Company Provides Update on Class Action

Takeda Pharmaceutical Company Limited Proposes Dividend

Takeda Pharmaceutical Company Limited to Report Q2, 2024 Results on Oct 26, 2023

Takeda Announces S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Takeda Pharmaceutical Company Limited Provides Dividend Guidance for the Fiscal Year 2023

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

Takeda Pharmaceutical Company Limited Announces FDA Approves the Supplemental Biologics License Application for the Expanded Use of TAKHZYRO

Takeda Pharmaceutical Company Limited Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Takeda Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on May 11, 2023

Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC

Arrowhead Pharmaceuticals Inc. and Takeda Pharmaceutical Company Limited Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Takeda Pharmaceutical Company Limited Announces Favorable Phase 3 Safety and Efficacy Results of TAK-755 as Compared to Standard of Care in Congenital Thrombotic Thrombocytopenic Purpura

Takeda’S Phase 3 Aurora Study Provides Evidence of Maribavir’S Clinically Meaningful and Durable Effect in Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Patients, Despite Missing Primary Endpoint

Takeda's Qdenga(R) Dengue Tetravalent Vaccine [Live, Attenuated]) Approves for Use in European Union

Takeda Pharmaceutical Company Limited Announces the U.S. Food and Drug Administration Accept and Grant Priority Review of the Biologics License Application for TAK-003

Takeda Announces Phase 3 Trial of Iclusig (Ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, Setting with No Targeted Treatments Approved in the US

Takeda Announces European Commission Approves LIVTENCITY (Maribavir) for Treatment of Adults with Post-Transplant Cytomegalovirus Infection and/or Disease that are Refractory (with or without Resistance) to One or More Prior Therapies

Takeda Pharmaceutical Company Limited to Report Q3, 2023 Results on Feb 02, 2023

Takeda Pharmaceutical Company Limited Revised Earnings Guidance for the Full Year of 2022

Takeda Receives Positive CHMP Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic Countries

U.S. Food and Drug Administration Accepts Takeda Pharmaceutical Company Limited's Supplemental Biologics License Application for Use of TAKHZYRO to Prevent Hereditary Angioedema Attacks in Children 2 Years of Age and Older

Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Post-Transplant Cytomegalovirus (CMV) Refractory (With or Without Resistance) to Prior Therapies

Takeda Launches CDPath, A Personalized Prognostic Tool, Advancing Innovation for Patients with Crohn's Disease

Takeda’s QDENGA® (Dengue Tetravalent Vaccine [Live, Attenuated]) Approves in Indonesia for Use Regardless of Prior Dengue Exposure

Shareholder Returns